Regeneron: Fairly Valued Now After A Stellar Upswing
2026-03-11 09:47:27 ET
Regeneron Pharmaceuticals, Inc. ( REGN ) is a well-established biotech company based in Tarrytown, NY, that has had a phenomenal journey since its founding in 1988, but most clearly – for shareholders – since it reached an inflection point in 2011 when the company received its first FDA approval (for its eye medication, Eylea). Shares are up a whopping 2,100% since then (from $33 to $770 today), which has handily outperformed the S&P 500 (SP500). As seen from the chart below, significant drawdowns of 30-50% are quite common throughout its history, with shares now trading 36% below the all-time high of around $1200 in August 2024....
Read the full article on Seeking Alpha
For further details see:
Regeneron: Fairly Valued Now After A Stellar Upswing
NASDAQ: REGN
REGN Trading
-3.4% G/L:
$754.90 Last:
201,922 Volume:
$764.06 Open:
